Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab As a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis.
Cureus（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined